NCT07448909 · NOT YET RECRUITING

Cognitive-Frailty Gait Biomechanics for Early Dementia Detection

This study is comparing how people with mild cognitive impairment walk, move, and score on a blood marker called BDNF — a protein linked to brain health — versus healthy older adults. It is an observational study, not a treatment trial, meaning no drug or therapy is being tested. Participants complete one session of physical measurements, a walking assessment, and a blood draw. Details on phase are not provided, as this is a data-collection study, not a clinical drug trial.

Eligibility criteria

Inclusion Criteria:
* Older adults aged 50 years and above
* Able to ambulate independently without the use of walking aids
* Must be able to understand instructions, communicate effectively
* Free from any acute or unstable medical conditions at the time of assessment.
Healthy older adults group:
-No history or symptoms of cognitive impairments and have normal cognitive screening results.
Mild Cognitive Impairment (MCI) group:
-Must fulfill established diagnostic criteria for MCI, showing measurable cognitive decline without significant functional impairment and without a diagnosis of dementia.
Exclusion Criteria:
* Present with any diagnosed neurological disorder such as stroke or Parkinson's disease
* History of psychiatric illness, including major depressive disorder.
* Individuals with uncontrolled cardiovascular, metabolic, or endocrine conditions
* Have significant visual, auditory, or musculoskeletal impairments that may influence gait performance
* Currently taking medications known to affect cognitive or motor function
* Unable to provide written informed consent

The sponsor's own eligibility wording, lightly reformatted. The study team makes the final eligibility decision — worth discussing with your doctor.

Eligibility criteria as of 2026-03-04

View full record on ClinicalTrials.gov

All APOE4 clinical trials